Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
July 29, 2014, 07:55:25 AM

Login with username, password and session length


Members
Stats
  • Total Posts: 632202
  • Total Topics: 47872
  • Online Today: 227
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online
Users: 7
Guests: 139
Total: 146

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: FDA Approves New HIV Treatment  (Read 3580 times)

0 Members and 1 Guest are viewing this topic.

Offline monarc

  • Member
  • Posts: 20
FDA Approves New HIV Treatment
« on: May 27, 2011, 01:21:26 AM »
http://www.medicalnewstoday.com/releases/226524.php

FDA Approves New HIV Treatment

The U.S. Food and Drug Administration approved Edurant (rilpivirine) in combination with other antiretroviral drugs for the treatment of HIV-1 infection in adults who have never taken HIV therapy (treatment-naive).

Edurant belongs to a class of HIV drugs called non-nucleoside reverse transcriptase inhibitor (NNRTI). The drug works by blocking HIV viral replication. Edurant is to be used as part of a highly active antiretroviral therapy (HAART) regimen that is designed to suppress the amount of HIV (viral load) in the blood. Edurant is a pill taken once a day with food.

"Patients may respond differently to various HIV drugs or experience varied side effects. FDA's approval of Edurant provides an additional treatment option for patients who are starting HIV therapy," said Edward Cox, M.D., M.P.H, director, Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research.

The safety and effectiveness of Edurant is based on 48-week data from two Phase 3 clinical trials with 1,368 adult subjects with HIV infection, and from a 96-week (with extension to 192 weeks) trial. Patients had not received prior HIV therapy and were selected to receive treatment with Edurant or efavirenz (another FDA-approved NNRTI for the treatment of HIV infection). Both drugs were given in combination with other antiretroviral drugs.

Edurant was as effective as efavirenz in lowering viral load. In the Edurant and efavirenz groups, 83 percent and 80 percent of subjects, respectively, had undetectable amounts of HIV in their blood after 48 weeks of treatment. Patients receiving Edurant who had a higher viral load at the start of therapy were more likely not to respond to the drug than were patients with a lower viral load at the start of therapy. In addition, persons who failed therapy with Edurant developed more drug resistance than patients who failed efavirenz.

The most commonly reported side effects in patients taking Edurant included depression, difficulty sleeping (insomnia), headache and rash. Fewer patients stopped taking the drug due to side effects as compared to patients taking efavirenz.

Edurant does not cure HIV infection. Patients must stay on continuous HIV therapy to control HIV infection and decrease HIV-related illnesses.

Edurant is manufactured by Raritan, N.J.-based Tibotec Therapeutics, a division of Centocor Ortho Biotech Inc.

Offline Hellraiser

  • Member
  • Posts: 4,136
  • Semi-misanthropic
Re: FDA Approves New HIV Treatment
« Reply #1 on: May 28, 2011, 02:43:34 AM »
The U.S. Food and Drug Administration approved Edurant (rilpivirine) in combination with other antiretroviral drugs for the treatment of HIV-1 infection in adults who have never taken HIV therapy (treatment-naive).

What?  Why would this be only for the treatment naive?

Offline monarc

  • Member
  • Posts: 20
Re: FDA Approves New HIV Treatment
« Reply #2 on: May 28, 2011, 07:43:23 AM »
What?  Why would this be only for the treatment naive?

I guess this could be:
Quote
In addition, persons who failed therapy with Edurant developed more drug resistance than patients who failed efavirenz.

I wonder if subjects got so resistant that the other drugs wouldn't work anymore.

Offline Miss Philicia

  • Member
  • Posts: 23,891
  • celebrity poster, faker & poser
Re: FDA Approves New HIV Treatment
« Reply #3 on: May 28, 2011, 11:27:04 AM »
What?  Why would this be only for the treatment naive?

This is accurate, though I realize it's the reverse of the most recent FDA approvals (Prezista, Isentress, etc.) details are mentioned here: http://www.aidsmeds.com/archive/Edurant_1619.shtml

Quote
Edurant may be less effectiveóable to keep viral load undetectable for at least a yearófor people beginning an Edurant-based regimen with a pre-treatment viral load of greater than 100,000 copies, compared with those with a pre-treatment viral load of less than 100,000 copies.
 
Compared with patients who took the NNRTI Sustiva (efavirenz) plus Truvada (tenofovir/emtricitabine) in clinical trials, people living with HIV who used Edurant plus Truvada were more likely to see their viral loads rebound while on treatment. Edurant-treated patients were also more likely to develop drug resistance to Truvada, compared with those using Sustiva.
"Iíve slept with enough men to know that Iím not gay"

Offline Hellraiser

  • Member
  • Posts: 4,136
  • Semi-misanthropic
Re: FDA Approves New HIV Treatment
« Reply #4 on: May 28, 2011, 03:30:26 PM »
This is accurate, though I realize it's the reverse of the most recent FDA approvals (Prezista, Isentress, etc.) details are mentioned here: http://www.aidsmeds.com/archive/Edurant_1619.shtml


I was waiting for this drug to swap to it, I guess that idea is out the window now.

Offline Miss Philicia

  • Member
  • Posts: 23,891
  • celebrity poster, faker & poser
Re: FDA Approves New HIV Treatment
« Reply #5 on: May 28, 2011, 03:45:49 PM »
I was waiting for this drug to swap to it, I guess that idea is out the window now.

I'd be less underwhelmed by this new drug, and not bothered by the resistance issue (which seems perhaps no worse than Isentress) if it exhibited a marked decrease in the CNS issues that Sustiva has, but while IIRC they are indeed less in the studies, I'm not sure it's what one could call "greatly less". I think it may have been 3% of participants versus 7% for the Sustiva group. We shall see. I guess I shouldn't poo-poo a~50% reduction.

That said there are still two more once-daily options coming from Gilead. I'm going to a Gilead sponsored HIV treatment presentation on 7 June and will see if I learn more about when they expect approval.
"Iíve slept with enough men to know that Iím not gay"

Offline surf18

  • Member
  • Posts: 525
Re: FDA Approves New HIV Treatment
« Reply #6 on: May 28, 2011, 05:09:35 PM »
My dr was going to switch me and I'm not treatment naive. Ko'd it because I'm on nexium.

Offline Hellraiser

  • Member
  • Posts: 4,136
  • Semi-misanthropic
Re: FDA Approves New HIV Treatment
« Reply #7 on: May 29, 2011, 04:11:10 AM »
I'd be less underwhelmed by this new drug, and not bothered by the resistance issue (which seems perhaps no worse than Isentress) if it exhibited a marked decrease in the CNS issues that Sustiva has, but while IIRC they are indeed less in the studies, I'm not sure it's what one could call "greatly less". I think it may have been 3% of participants versus 7% for the Sustiva group. We shall see. I guess I shouldn't poo-poo a~50% reduction.

That said there are still two more once-daily options coming from Gilead. I'm going to a Gilead sponsored HIV treatment presentation on 7 June and will see if I learn more about when they expect approval.

Please do and bring some information back for me :)  I may have been thinking that the new B-tripla was supposed to use this drug in it's formulation, but a lot of this information was being talked about when I was newly diagnosed so it flew over my head at the time.

http://www.youtube.com/watch?v=N6uEMOeDZsA

Offline flip408

  • Member
  • Posts: 21
Re: FDA Approves New HIV Treatment
« Reply #8 on: June 05, 2011, 08:21:56 PM »
I think naive and non naive are on different FDA approval tracks.  For example there would be a clinical trial for treatment naive and a separate clinical trial for non naive.  Seems like they would do the treatment naive first, followed by non naive. 

I am on the rilpivirene/truvada trial for non naive, phase 3, I am at week 12 of 48 week study.
Start where you are, use what you have, do what you can.    A Ashe
05/14/11  501  <50  20%
4/14/11  483  <50  19%
2/10/11    523  <50 18% start Rilpivr/trvda
11/15/10  470  <50
1/6/10    430  <50  16%
7/13/09  345  <50  12%
1/26/09  347  <50  16%
7/22/08  306  <50  6%
11/26/07 238 <50  8%
6/11/07  253  <50  5%
11/9/06  122  <50 7%
9/05/06  <25 >100000  PCP

Offline Miss Philicia

  • Member
  • Posts: 23,891
  • celebrity poster, faker & poser
Re: FDA Approves New HIV Treatment
« Reply #9 on: June 11, 2011, 11:14:52 PM »
Seems like they would do the treatment naive first, followed by non naive. 

No, for the past decade it's been the reverse -- emphasis always on patients with resistance issues. Silly, really isn't it -- let's just let them die off!
"Iíve slept with enough men to know that Iím not gay"

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.